$6.12+0.13 (+2.17%)
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
Verrica Pharmaceuticals Inc. in the Healthcare sector is trading at $6.12 with a market capitalization of $101M. Wall Street consensus targets $15.54 (5 analysts), implying a +154.0% move over the next 12 months. The stock is currently 38% below its 52-week high of $9.82, remaining 3.7% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combin...
On Tuesday, Verrica Pharmaceuticals (NASDAQ:VRCA) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://viavid.webcasts.com/starthere.jsp?ei=1758586&tp_key=307852c58b Summary Verrica Pharmaceuticals Inc reported a total revenue of $5 million for Q1 2026,
Verrica Pharmaceuticals Inc (VRCA) reports significant revenue growth and strategic milestones, despite facing financial and operational hurdles.
Verrica Pharmaceuticals (NASDAQ:VRCA) reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma. President and Chief Executive Officer Jayson Rieger sai
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +30.51% and +6.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Lipocine (LPCN) delivered earnings and revenue surprises of -5.88% and +19.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?